

Kymab granted leave to appeal to the UK Supreme Court

Cambridge, UK; 30 November 2018: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics, announces that it has received permission to appeal the decision of the UK Court of Appeal to overturn the decision of the High Court trial judge, Mr. Justice Henry Carr, to revoke two patents (European Patent EP(UK) 1 360 287 and EP(UK) 2 264 163) owned by Regeneron.

The patents in question seek to cover genetically modified mice containing human antibody variable region loci and humanised antibodies from such mice. The High Court decided on 1 February 2016, in agreement with Kymab, that Regeneron's patents were invalid as they failed to disclose sufficient information to allow the claimed inventions to be performed. The decision of the High Court was subsequently overturned by the Court of Appeal.

Permission to appeal to the Supreme Court has been granted on the grounds that the Court of Appeal wrongly interpreted and applied the law of insufficiency.

###ENDS###

Notes to Editors

About Kymab

Kymab a clinical-stage biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.

Kymab's platform has been designed to maximize the diversity of human antibodies produced in response to immunization with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently. Kymab is leveraging its platform for its internal drug discovery programs and in partnership with pharmaceutical companies.

For more information please see <http://www.kymab.com>. Kymab is a trademark of Kymab Limited.